The study suggests that microRNA-101 targets DUSP1 and downregulates DUSP1 expression, and sorafenib treatment upregulates DUSP1 expression in macrophage M2 cells, which leads to lower TGF-beta and CD206 release in HCC-TME and thus suppresses HCC progression.155. This evidence concerns the gene DUSP1 and hepatocellular carcinoma.